Sun Pharma Q1 Review — Dolat Capital Maintains 'Reduce', Sees Current Valuations To Limit Upside
Sun Pharma's India revenues demonstrated strong growth of 13.9% YoY in Q1 FY26, driven by volume and new introductions. The company launched five new products in the Indian market during Q1 FY26 and holds the No. 1 position for prescriptions in 13 different doctor categories.
NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
We expect Sun Pharmaceutical Industries Ltd.'s revenue/PAT CAGR of 9%/7% over FY25-27E. With limited upside from current levels, we maintain ‘Reduce' rating, with a revised target price of Rs 1,696 at 30x FY27E P/E.
Key upside will be higher-than-expected traction in specialty sales and US growth.
Key downside will be further escalation of regulatory issues on plants and price erosion in base generics.
Sun Pharma's Q1 FY26 sales came in line with estimates, while Ebitda (exforex) came above due to lower-than-expected research and development and other expenses. PAT, adjusted for the exceptional items, fell in line.
Adj PAT fell in line despite higher operating performance due to higher-than-expected tax rate, lower-than-expected other income and higher-than-expected interest cost. The tax rate guidance for FY26 is around 25% higher than FY25.
We downgrade our FY26E/FY27E EPS estimate by -4.4%/-4.1%, assuming higher tax rate. Maintain ‘Reduce' rating with a revised TP of Rs 1,696 at 30x FY27E P/E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.